γH2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma

Eiko Sakurai 1, Hisato Ishizawa 2, Yuka Kiriyama 1,3, Ayano Michiba 1, Yasushi Hoshikawa 2 and Tetsuya Tsukamoto 1,*

1 Department of Diagnostic Pathology, Graduate School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Japan; eiko.sakurai@fujita-hu.ac.jp (E.S.); ykiri@fujita-hu.ac.jp (Y.K.); michiba1511@gmail.com (A.M.)
2 Department of Thoracic Surgery, Graduate School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Japan; h-ishi@fujita-hu.ac.jp (H.I.); yasushih@fujita-hu.ac.jp (Y.H.)
3 Department of Diagnostic Pathology, Narita Memorial Hospital, 134, Haneihonmachi, Toyoashi 441-8029, Japan
* Correspondence: ttsukamt@fujita-hu.ac.jp; Tel.: +81-562-93-9763

Abstract: In recent years, the choice of immune checkpoint inhibitors (ICIs) as a treatment based on high expression of programmed death-ligand 1 (PD-L1) in lung cancers has been increasing in prevalence. The high expression of PD-L1 could be a predictor of ICI efficacy as well as high tumor mutation burden (TMB), which is determined using next-generation sequencing (NGS). However, a great deal of effort is required to perform NGS to determine TMB. The present study focused on γH2AX, a double-strand DNA break marker, and the suspected positive relation between TMB and γH2AX was investigated. We assessed the possibility of γH2AX being an alternative marker of TMB or PD-L1. One hundred formalin-fixed, paraffin-embedded specimens of lung cancer were examined. All of the patients in the study received thoracic surgery, having been diagnosed with lung adenocarcinoma or squamous cell carcinoma. The expressions of γH2AX and PD-L1 (clone: SP142) were evaluated immunohistochemically. Other immunohistochemical indicators, p53 and Ki-67, were also used to estimate the relationships of γH2AX. Positive relationships between γH2AX and PD-L1 were proven, especially in lung adenocarcinoma. Tobacco consumption was associated with higher expression of γH2AX, PD-L1, Ki-67, and p53. In conclusion, the immunoexpression of γH2AX could be a predictor for the adaptation of ICIs as well as PD-L1 and TMB.

Keywords: lung cancer; adenocarcinoma; squamous cell carcinoma; immune checkpoint inhibitors; programmed death-ligand 1; DNA damage response; γH2AX; smoking; Brinkman index

1. Introduction

Lung cancer is a common cause of cancer mortality in most developed countries worldwide [1]. Tobacco smoking is one of the most significant causes of cancer development. Many carcinogens found in tobacco have been reported to directly damage and mutate DNA [2]. Although various treatments, including surgery, neoadjuvant chemotherapy, and adjuvant chemotherapy, have been applied to lung cancer patients, the prognosis for these individuals is still poor. In recent years, molecular targeting therapies have been developed and have contributed to a better prognosis for lung cancer.

Tumor mutation burden (TMB) is the total number of somatic missense mutations in the coding genome of tumor tissue or blood samples using whole-exome sequencing. TMB represents the number of mutations per megabase (muts/Mb), and high TMB was defined as being more than 10 muts/Mb [3]. High TMB has been reported to be a biomarker of sensitivity to immune checkpoint inhibitors (ICIs). Although TMB is useful when deciding upon ICI application, the measurement of TMB is costly, labor-intensive, and time-consuming to perform, as it requires next-generation sequencing. Sabari et al. reported...
that the median turnaround time (TAT) for tissue next-generation sequencing (NGS) was 20 days [4]. PD-L1, which is a ligand of membrane-bound molecule programmed death 1 (PD-1), belongs to the immune checkpoint pathway and is also an indicator for the adaptation of ICIs as well as TMB.

H2AX is a variant of the histone H2A protein, which composes a histone octamer in nucleosomes. Phosphorylated H2AX at the Ser-139 position, called γH2AX, is one of the earliest cellular responses of DNA double-strand breaks. DNA double-strand breaks are induced by ionizing radiation and cytotoxic chemotherapy. The overexpression of γH2AX in cancer cells has been reported in various cancer types [5–10]. We hypothesized that the high expression of γH2AX in cancer cells could indicate the high frequency of repairing DNA damage and lead to the high frequency of missense mutations. Therefore, the high expression of γH2AX in cancer might result in high TMB.

Here, we assessed the significance of γH2AX expression as a predictor of the adaptation of ICIs by comparing the immunohistochemical expression of γH2AX with PD-L1. In conclusion, γH2AX, a DNA double-strand break marker, significantly correlated with PD-L1 expression in lung adenocarcinomas, and could be a useful biomarker when deciding upon ICI usage.

2. Results

2.1. Comparison between Clinicopathological Parameters of Lung Adenocarcinoma and Squamous Cell Carcinoma

Patients were classified as having lung adenocarcinomas or squamous cell carcinomas (Table 1, left panel). There was a greater number of squamous cell carcinomas in men than in women. Adenocarcinomas tend to have lower histological grades than squamous cell carcinomas.

| Table 1. Clinicopathological characteristics. | Histology |  | γH2AX |  |
| --- | --- | --- | --- | --- |
| **Histology** | Adenocarcinoma | Squamous Cell Carcinoma |  | High (6–100%) | Low (0–5%) |  |
| Number of cases | 51 | 49 |  | 65 | 35 |  |
| Age |  |  |  |  |  |  |
| ≥70 | 28 | 32 | 0.3138 | 41 | 19 | 0.402 |
| <70 | 23 | 17 |  | 24 | 16 |  |
| Sex |  |  |  |  |  |  |
| Male | 36 | 44 | 0.0235 | 58 | 22 | 0.0032 |
| Female | 15 | 5 |  | 7 | 13 |  |
| Histology |  |  |  |  |  |  |
| Adenocarcinoma | 51 | 0 | NA | 22 | 29 | <0.0001 |
| Squamous cell carcinoma | 0 | 49 |  | 43 | 6 |  |
| Fibrosis |  |  |  |  |  |  |
| Fibrosis | 25 | 26 | 0.6948 | 36 | 15 | 0.2953 |
| Non-fibrosis | 26 | 23 |  | 29 | 20 |  |
| Histological grade |  |  |  |  |  |  |
| G1–2 | 48 | 38 | 0.0215 | 55 | 31 | 0.7651 |
| G3 | 3 | 11 |  | 10 | 4 |  |
| pT |  |  |  |  |  |  |
| Tis–T1 | 30 | 27 | 0.8401 | 32 | 25 | 0.0366 |
| T2–T4 | 21 | 22 |  | 33 | 10 |  |
| pStage |  |  |  |  |  |  |
| 0–I | 37 | 34 | 0.8117 | 47 | 31 | 0.0779 |
| II–III | 13 | 10 |  | 18 | 4 |  |
| pN |  |  |  |  |  |  |
| pN0 | 42 | 43 | 0.578 | 54 | 31 | 0.5658 |
| pN1–3 | 9 | 6 |  | 11 | 4 |  |
# Table 1. Cont.

| Histology          | p Value | γH2AX |
|--------------------|---------|-------|
|                    | High    | Low   |
|                    | (6–100%) | (0–5%) | p Value |
| Ly                 |         |       |
| Ly0                | Ly1     |       |
| V                  |         |       |
| V0                 | V1–2    |       |
| pm                 |         |       |
| pm0                | pm1–3   |       |
| pl                 |         |       |
| pl0                | pl1–3   |       |

| Abbr.: Ly, lymphatic vessel invasion; V, vascular invasion; pm, pulmonary metastasis; pl, pleural invasion. |

## 2.2. Immunohistochemical Analysis of γH2AX, PD-L1, Ki-67, and p53 in Lung Adenocarcinomas and Squamous Cell Carcinomas

The expression of γH2AX, PD-L1, Ki-67, and p53 in lung adenocarcinomas and in lung squamous cell carcinomas was evaluated (Figures 1–3). It was shown that one case of adenocarcinoma (Figure 1) possessed low γH2AX and PD-L1 levels with wild-type p53 and a low Ki-67 level. Another adenocarcinoma case (Figure 2) surrounded by fibrotic stroma had higher levels of γH2AX and PD-L1. A case of squamous cell carcinoma was revealed to carry higher levels of those proteins (Figure 3). The merged figure of pseudo-fluorescent images of γH2AX (red) and PD-L1 (yellow) illustrates the similar distribution of those proteins.
Figure 1. Adenocarcinoma with low γH2AX and PD-L1 levels.

Figure 2. Adenocarcinoma with high γH2AX and PD-L1 levels surrounded by fibrous stroma.

Figure 3. Squamous cell carcinoma with high γH2AX and PD-L1 levels.

2.3. Relationship between γH2AX Expression and Clinicopathological Parameters

The expression level of γH2AX was subdivided into low (0–5%) and high (6%–100%).

Higher γH2AX expression was observed in men compared to women ($p = 0.0032$) and in squamous cell carcinomas compared to adenocarcinomas ($p < 0.0001$). More advanced pT ($p = 0.0366$) and more lymphatic duct invasion were observed in the higher γH2AX group ($p = 0.0366$ and $p = 0.0119$, respectively) (Table 1, right panel).

2.4. Difference in Expression of γH2AX, PD-L1, Ki-67, and p53 between Adenocarcinomas and Squamous Cell Carcinomas

The expression of γH2AX, PD-L1, Ki-67, and p53 in squamous cell carcinomas was higher than in adenocarcinomas ($p < 0.0001$ in all) (Figure 4).

Figure 2. Adenocarcinoma with high γH2AX and PD-L1 levels surrounded by fibrous stroma.

Figure 3. Squamous cell carcinoma with high γH2AX and PD-L1 levels.
2.3. Relationship between γH2AX Expression and Clinicopathological Parameters

The expression level of γH2AX was subdivided into low (0–5%) and high (6–100%). Higher γH2AX expression was observed in men compared to women ($p = 0.0032$) and in squamous cell carcinomas compared to adenocarcinomas ($p < 0.0001$). More advanced pT $(p = 0.0366)$ and more lymphatic duct invasion were observed in the higher γH2AX group $(p = 0.0366$ and $p = 0.0119$, respectively) (Table 1, right panel).

2.4. Difference in Expression of γH2AX, PD-L1, Ki-67, and p53 between Adenocarcinomas and Squamous Cell Carcinomas

The expression of γH2AX, PD-L1, Ki-67, and p53 in squamous cell carcinomas was higher than in adenocarcinomas $(p < 0.0001$ in all) (Figure 4).

2.5. Relationship between γH2AX Expression and the Immunohistochemical Expression of Other Indicators (PD-L1, Ki-67, and p53)

Cancers with higher γH2AX expression were associated with the higher expression of PD-L1, Ki-67, and p53 $(p < 0.0001$ each) (Table 2).

Table 2. Association between γH2AX and the expression of PD-L1, Ki-67, and p53.

| γH2AX       | PD-L1 (TC score) | Ki-67 | p53            |
|-------------|------------------|-------|----------------|
|             | High (6–100%)    | Low (0–5%) | $p$ Value |
| 0           | 20               | 26    | $<0.0001$      |
| 1, 2, 3     | 45               | 9     |                |
| Low (0–19%) | 11               | 23    | $<0.0001$      |
| High (20–100%) | 54              | 12    |                |
| Non-mutation| 14               | 23    | $<0.0001$      |
| Mutation    | 51               | 12    |                |

Figure 4. Comparison of immunohistochemical expression of γH2AX, PD-L1(TC), Ki-67, and p53 in adenocarcinomas (ADCs) and squamous cell carcinomas (SCCs).
2.6. Correlation between γH2AX and PD-L1 Expression

A positive relationship was found between γH2AX and PD-L1 expression in lung adenocarcinomas (\( p = 0.004 \), Pearson \( r = 0.3964 \)), whereas no statistical significance was found in lung squamous cell carcinomas (\( p = 0.1358 \), Pearson \( r = 0.216 \)) (Figure 5). Furthermore, a positive relationship was also found in lung adenocarcinomas without surrounding fibrosis, but no statistical significance was found in lung adenocarcinomas with fibrosis.

![Figure 5. Correlation of γH2AX and PD-L1 immunoexpression.](image)

2.7. Relationship between Smoking History (Brinkman Index) and the Expression of γH2AX, PD-L1, Ki-67, and p53

Regarding smoking history (Table 3) and lung cancer histology, most squamous cell carcinoma patients had higher Brinkman index scores compared to those with adenocarcinomas. The group of participants with more extensive smoking histories (Brinkman index ≥ 200) showed higher expressions of γH2AX (\( p < 0.0001 \)), PD-L1(TC score) (\( p = 0.0144 \)), Ki-67 (\( p = 0.018 \)), and p53 (\( p = 0.047 \)). With regard to γH2AX, according to the Brinkman index, there were significant differences in adenocarcinomas (\( p = 0.0349 \)), whereas no significant differences were shown in squamous cell carcinomas (\( p > 0.9999 \)).
Table 3. Associations between tobacco (Brinkman index) and histology, and the expression of γH2AX, PD-L1, Ki-67, and p53.

| Brinkman Index | ≥200 | <200 | Unknown | p Value |
|----------------|------|------|---------|---------|
| Histology      |      |      |         |         |
| Adenocarcinoma | 33   | 16   | 2       | <0.0001 |
| Squamous cell carcinoma | 44   | 1    | 4       |         |
| γH2AX          |      |      |         |         |
| Low (0–5%)     | 22   | 13   | 0       | <0.001  |
| High (6–100%)  | 55   | 4    | 6       |         |
| Adenocarcinoma |      |      |         |         |
| Low (0–5%)     | 16   | 13   | 0       | 0.0349  |
| High (6–100%)  | 17   | 3    | 2       |         |
| Squamous cell carcinoma |    |      |         |         |
| Low (0–5%)     | 6    | 0    | 0       | >0.9999 |
| High (6–100%)  | 38   | 1    | 4       |         |
| PD-L1 (TC score) |    |      |         |         |
| 0              | 32   | 13   | 1       | 0.0144  |
| 1,2,3          | 45   | 4    | 5       |         |
| Ki-67          |      |      |         |         |
| Low (0–19%)    | 22   | 12   | 0       | 0.0018  |
| High (20–100%) | 55   | 5    | 6       |         |
| p53            |      |      |         |         |
| Non-mutation   | 24   | 12   | 2       | 0.0047  |
| Mutation       | 53   | 5    | 4       |         |

2.8. Patient Survival

No statistical significance in terms of patient survival was detected in both high/low γH2AX expression and high/low PD-L1 expression (Figures 6, S1 and S2).

Figure 6. Kaplan–Meier log-rank test showing no statistically significant differences between high and low groups in γH2AX and in PD-L1.
3. Discussion

In recent years, the prognosis of non-small-cell carcinomas (NSCLCs) with oncogenic driver mutations has improved due to the development of molecularly targeted drugs. However, for NSCLCs without driver mutations, ICIs may be used as a treatment choice. In terms of predicting the effectiveness of ICIs, a high level of the immunoexpression of PD-L1, high TMB, microsatellite instability (MSI), and the tumor infiltration of immune cells indicate that this treatment would be effective. Although TMB is a direct indicator of DNA mutation, its determination requires time-consuming and costly NGS. Therefore, we investigated whether the immunostaining of γH2AX, a DNA double-strand break marker, could be a useful alternative method.

We proved a positive relation between the expression of γH2AX and PD-L1 in lung adenocarcinomas. For subpopulations of adenocarcinomas, positive correlation was confirmed between γH2AX and PD-L1 in adenocarcinoma without fibrosis with statistical significance in contrast to no association in adenocarcinoma with fibrosis [11–13]. Celada et al. [11] demonstrated that CD4+ T cells in fibrosis affected high PD-L1 expression and found that higher PD-L1 expression was shown in idiopathic pulmonary fibrosis (IPF) than in the controls. Kronborg-White et al. [12] also demonstrated upregulation of PD-L1 in pulmonary epithelial cells in IPF patients. Kunwar et al. [14] demonstrated that irradiation induced γH2AX expression and subsequent interstitial fibrosis. Taking into account these reports, γH2AX expression could be associated with PD-L1 expression in interstitial fibrosis. Further analysis may be required to assess the link between γH2AX and PD-L1 expression in adenocarcinoma with fibrosis. In lung squamous cell carcinomas in the present study, no statistical significance was found in correlation between these gene products. Osoegawa et al. reported [15] a positive relationship between γH2AX and PD-L1 expression in lung squamous cell carcinomas, which was determined using PD-L1 clone E1L3N. In the present report, clone SP142, the target therapy of which is atezolizumab, was applied. The outcome of PD-L1 expression might differ depending on the PD-L1 clone used. TMB may be related to tobacco-associated mutagens, but not correlated with PD-L1 expression [16]. Regarding tobacco exposure and PD-L1 expression, Li et al. [17] demonstrated positive correlation. In this study, a positive relationship between tobacco and γH2AX was proved. Depending on previous reports, including our own reports [16,17], the results of investigations between the relationship among PD-L1, γH2AX, and TMB have varied. Thus, this relationship must be examined in a larger number of cases.

The difficulty in evaluating PD-L1 immunohistochemically [18] should also be noted. In most cases, a mixture of high- and low-expression areas of PD-L1 was observed in each tumor because of the heterogeneity. As only one block of FFPE is usually selected for the determination of PD-L1 expression, the highest expression area might not have been included in the selected block. Non-tumor cells, for instance, inflammatory cells and necrotic cells, are also stained by PD-L1. In particular, alveolar macrophages are similar in morphology to cancer cells. It is sometimes difficult to distinguish tumor cells from other cells. The evaluation of PD-L1 by one investigator might not correspond with that of others. While TC (tumor cell) score was used in this study to avoid confusion, IC (immune cell) score was supposed to be included for clinical assessment. Furthermore, the preanalytical processing of tumor samples, including formalin fixation duration, should be properly controlled [19]. On the other hand, it is easier to evaluate γH2AX expression than PD-L1, because inflammatory cells are not stained normally, while necrotic cells are. Furthermore, with regard to γH2AX, it is easier to count positive cells because of its nuclear staining, whereas PD-L1 undergoes membrane staining.

The group of participants with extensive smoking histories (Brinkman index ≥ 200) had high expressions of γH2AX, PD-L1(TC score), Ki-67, and p53. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which is nitrosamine derived from tobacco and has been found to cause lung cancer. NNK is metabolized as an ultimate carcinogen by cytochrome 2A6. NNK has been considered to effect p53 mutation and mismatch DNA repair [20,21]. There was a report of the overexpression of Ki-67 or p53 observed in rats who received toxic
doses of NNK [22]. The relationship between NNK and γH2AX has also been reported [23]. It was suggested that tobacco-induced carcinogens might induce p53 mutation and the overexpression of γH2AX and Ki-67. The result of high γH2AX expression related to high expression in p53 and Ki-67 could also support this suggestion.

The proper and quick adaptation of ICIs is a major concern, because ICIs might represent a last strategy for the treatment of advanced stages of NSCLCs and NSCLCs without oncogenic driver mutations [24]. Complications regarding ICIs could be fatal in some cases [25], so patients selected for treatment with ICIs must be selected with the utmost caution. Immunohistochemical methods could save time in starting treatment compared to NGS. To make it easy to determine immunohistochemically positive cells, a method must enable uniform evaluation by any judge. The immunostaining of γH2AX is suggested to be a greatly useful method for determining adaptation for ICIs. A larger number of cases needs to be studied. These results warrant further analysis.

In conclusion, a positive relationship between γH2AX with PD-L1 was proven in lung adenocarcinomas. γH2AX could be a predictor of the adaptation of ICIs as an alternative to TMB or PD-L1.

4. Materials and Methods

4.1. Study Subject

Formalin-fixed, paraffin-embedded (FFPE) specimens from 100 consecutive patients with lung carcinomas were examined. Patients underwent thoracic surgery at Fujita Health University Hospital between February 2015 and August 2020. Their clinicopathological characteristics are shown in Table 1. In total, 80 males and 20 females (age range: 38–87 years; mean: 69.92) were included. Pathological diagnosis was performed according to the fourth edition of the World Health Organization criteria [26] and the eighth edition of the TNM classification of Lung Cancer [27]. In total, 51 patients had lung adenocarcinomas and 49 had squamous cell carcinomas. Lung fibrosis detected with computed tomography was also included to subclassify the carcinomas; 25 and 26 cases involved adenocarcinomas with fibrosis and squamous cell carcinomas with fibrosis, respectively (Table 1).

The Brinkman index, which determines the total amount of tobacco smoking in an individual, was calculated by multiplying the number of cigarettes/day by years of smoking history. Pack-year is 1/20 of the Brinkman index. In the present study, a Brinkman index of 200 was selected as the cut-off value, because the Ministry of Health, Labor, and Welfare of the Japanese Government determined this number or above should be used for the clinical management for tobacco cessation [28].

The use of archived FFPE material of human cases was approved by the Institutional Review Board of Fujita Health University on 23 January 2021 (HM20-326).

4.2. Immunohistochemistry

Immunohistochemical investigation was performed using tissue specimens sliced from FFPE. Sections 3 µm thick were deparaffinized in xylene and hydrated in a series of graded ethanol dilutions. Endogenous peroxidase was blocked at room temperature by 0.1% hydrogen peroxide in methanol for 30 min. Heat-induced epitope retrieval was performed in ethylenediaminetetraacetic acid (EDTA) (pH 8.0) and using a pressure cooker for 10 min. The sections were incubated with primary antibodies against γH2AX (rabbit monoclonal, clone 20E3; Cell Signaling Technology, Danvers, MA, 1:1000 dilution), Ki-67 (mouse monoclonal, clone MIB-1; DAKO, Glostrup, Denmark, 1:100 dilution), and p53 (mouse monoclonal, clone DO-7; Novocastra, Newcastle upon Tyne, UK, 1:100 dilution).

After being washed, the sections were incubated in goat antimouse/rabbit immunoglobulin labeled with horseradish peroxidase (Histofine Simple Stain MAX-PO, Nichirei, Tokyo) for 30 min at room temperature. Staining was visualized using 3,3′-diaminobenzidine as a chromogen. The slides were then counterstained with hematoxylin. The immunohistochemistry of PD-L1 (mouse monoclonal, clone SP142; Abcam, Cambridge, UK, 1:200 dilution)
was performed by using BOND RX Fully Automated Research Stainer (Leica Biosystems, Wetzlar, Germany).

Immunostained slides were evaluated as follows: high γH2AX expression if >5% of tumor cells demonstrated nuclear staining, and high Ki-67 expression if >20% of tumor cells demonstrated nuclear staining. PD-L1 was scored according to the Ventana Optiview PD-L1 (SP142) Judgment guide lung-cancer [29]. PD-L1 TC scores of 0, 1, 2, or 3 were used for our investigation. p53 expression was evaluated by multiplying the intensity (1, 2, or 3, from weak to strong) and proportion (0.0–1.0); a score of more than 1.0 was considered to be abnormal accumulation by mutation.

4.3. Merging Multiple Immunohistochemical Images by Utilizing HALO Software (Indica Labs)

Whole-slide images (WSI) of HE and immunohistochemistry were created with a WSI scanner, AxioScan.Z1 (Zeiss, Oberkochen, Germany), using a 20× objective lens. First, immunohistochemical WSI images of γH2AX and PD-L1 were converted to red and yellow pseudo-immunofluorescent images, respectively, and merged views were created using HALO image analysis software (Indica Labs, Albuquerque, New Mexico).

4.4. Statistical Analysis

Statistical analysis of the data was performed using Prism 7 (GraphPad, San Diego, CA, USA) and SPSS version 23.0 (IBM, Armonk, NY, USA). The Chi-square test was used to evaluate the association between the molecular expression and the clinicopathological parameters. Pearson’s correlation coefficient (Pearson r) was calculated to evaluate the correlation between γH2AX and PD-L1 expression. The patient survival values were calculated from the day of surgery until death, in months, using the Kaplan–Meier method. p values less than 0.05 were considered to be statistically significant.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23126679/s1.

Author Contributions: E.S. carried out histopathological evaluation and drafted the manuscript. T.T. conceived of the study and participated in the design and preparation of the manuscript. T.T., Y.K. and A.M. evaluated the histopathological findings. H.I. and Y.H. collected, evaluated, and interpreted the clinical data. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by a grant-in-aid for Scientific Research from Fujita Health University 2021 awarded to T.T.

Institutional Review Board Statement: This study using human materials was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Fujita Health University (Approval No. HM20-326) on 23 January 2021.

Informed Consent Statement: Informed consent was obtained from all of the subjects for research use, while they retained the option to opt out of this study.

Data Availability Statement: Data will not be made available, but the data that support the findings of this study are available upon reasonable request to the corresponding author.

Acknowledgments: The authors thank Mika Maejima, Megumi Miyamoto and Natsuki Yazawa for their helpful assistance.

Conflicts of Interest: The authors declare that they have no competing interests.

References

1. Schabath, M.B.; Cote, M.L. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol. Biomarkers Prev. 2019, 28, 1563–1579. [CrossRef] [PubMed]

2. Yoshida, K.; Gowers, K.H.C.; Lee-Six, H.; Chandrasekharan, D.P.; Coorens, T.; Maughan, E.F.; Beal, K.; Menzies, A.; Millar, F.R.; Anderson, E.; et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 2020, 578, 266–272. [CrossRef] [PubMed]

3. Pan, D.; Hu, A.Y.; Antonia, S.J.; Li, C.Y. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. J. Thorac. Oncol. 2021, 16, 419–427. [CrossRef] [PubMed]
4. Sabari, J.K.; Offin, M.; Stephens, D.; Ni, A.; Lee, A.; Pavlakis, N.; Clarke, S.; Diakos, C.I.; Datta, S.; Tandon, N.; et al. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. *J. Natl. Cancer Institute* 2019, 111, 575–583. [CrossRef]

5. Palla, V.V.; Karaoianis, G.; Katafigiotis, I.; Anastasiou, I.; Patapis, P.; Dimitroulis, D.; Perrea, D. gamma-H2AX: Can it be established as a classical cancer prognostic factor? *Tumour Biol.* 2017, 39, 1010428317695931. [CrossRef] [PubMed]

6. Matthais, D.; Foukas, P.G.; Kefala, M.; Hourtis, P.; Trypsiantides, I.G.; Chatzaki, E.; Pantelidaki, E.; Bouros, D.; Karakitsos, P.; et al. The y-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. *Onco Targets Thera.* 2012, 5, 309–314. [CrossRef]

7. Miyazawa, T.; Marushima, H.; Saji, H.; Kojima, K.; Hoshikawa, M.; Takagi, M.; Nakamura, H. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. *Ann. Thorac. Cardiovasc. Surg.* 2019, 25, 0a-18. [CrossRef] [PubMed]

8. Brunner, A.H.; Hinterholzer, S.; Byun, S.W.; Chang, Y.J.; Kim, J.S.; Kim, J.K.; Cho, H.J.; Lim, K.W.; Jung, E.S. Double strand break of DNA in gastric adenoma and adenocarcinoma. *Korean J. Gastroenterol.* 2010, 55, 19–25. [CrossRef]

9. Hu, J.L.; Hu, S.S.; Hou, X.X.; Zhu, X.; Cao, J.; Jiang, L.H.; Ge, M.H. Abnormal Expression of DNA Double-Strand Breaks Related Genes, ATM and GammaH2AX, in Thyroid Carcinoma. *Int. J. Endocrinol.* 2015, 2015, 136810. [CrossRef] [PubMed]

10. Kim, J.H.; Kim, S.S.; Byun, S.W.; Chang, Y.J.; Kim, J.S.; Kim, J.K.; Cho, H.J.; Lim, K.W.; Jung, E.S. Double strand break of DNA in thoracic radiation exposure in mice. *J. Clin. Med.* 2021, 10, 5562. [CrossRef]

11. Celada, L.J.; Kropski, J.A.; Herazo-Mayo, J.D.; Luo, W.; Creecy, A.; Abad, A.T.; Chioma, O.S.; Lee, G.; Hassell, N.E.; Shaginurova, G.I.; et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. *Sci. Transl. Med.* 2018, 10, eaar8356. [CrossRef]

12. Kronborg-White, S.; Madsen, L.B.; Bendstrup, E.; Poletti, V. PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. *J. Clin. Med.* 2020, 9, 660–669. [CrossRef]

13. Osoegawa, A.; Drosdick Milenkovic, M.; Kotur Steviljevic, J.; Markovic, J.; Cerman, V.; Kontic, M.; Skodoric Trifunovic, V. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. *J. Thorac. Dis.* 2018, 10, 171–177. [CrossRef] [PubMed]

14. Kunwar, A.; Haston, C.K. DNA damage at respiratory distress, but not acute time-points, correlates with tissue fibrosis following thoracic radiation exposure in mice. *J. Radiat. Biol.* 2015, 91, 360–367. [CrossRef] [PubMed]

15. Osoegawa, A.; Hiraishi, H.; Hashimoto, T.; Takumi, Y.; Abe, M.; Takeuchi, H.; Miyawaki, M.; Okamoto, T.; Sugio, K. The Positive Relationship between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. *In Vivo* 2018, 32, 171–177. [CrossRef] [PubMed]

16. Osoegawa, A.; Takada, K.; Okamoto, T.; Sato, S.; Nagahashi, M.; Tagawa, T.; Tsuchida, M.; Oki, E.; Okuda, S.; Wakai, T.; et al. Mutational signatures in squamous cell carcinoma of the lung. *J. Thorac. Dis.* 2021, 13, 1075–1082. [CrossRef] [PubMed]

17. Li, J.J.N.; Karim, K.; Sung, M.; Le, L.W.; Lau, S.C.M.; Sacher, A.; Leighl, N.B. Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. *Lung Cancer* 2020, 150, 159–163. [CrossRef] [PubMed]

18. Skov, B.G. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting. *Appl. Immunohistochem. Mol. Morphol.* 2021, 29, 49–55. [CrossRef] [PubMed]

19. Barber, A.; Marginet Flinch, R.; Martin, M.; Mate, J.L.; Oriol, A.; Martínez-Ayerbe, L.; Vázquez, S.; Turpin, J.; Martínez-Soler, F.; Santalucia, T.; Fernandez, P.L. The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation. *Appl. Immunohistochem. Mol. Morphol.* 2021, 29, 76–81. [CrossRef] [PubMed]

20. Shen, Y.; Zhang, S.; Huang, X.; Chen, K.; Shen, J.; Wang, Z. Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells. *BioMed Res. Int.* 2014, 2014, 920275. [CrossRef] [PubMed]

21. Doukas, S.G.; Vageli, D.P.; Lazoropoulos, G.; Spandidos, D.A.; Sasaki, C.T.; Tsatsakis, A. The Effect of NNK, A Tobacco Smoke Carcinogen, on the miRNA and Mismatch DNA Repair Expression Profiles in Lung and Head and Neck Squamous Cancer Cells. *Cells* 2020, 9, 1031. [CrossRef]

22. El-Kenawy Ael, M.; Elshama, S.S.; Osman, H.E. Effects of Physalis peruviana L. on Toxicity and Lung Cancer Induction by Nicotine Derived Nitrosamine Ketone in Rats. *Asian Pac. J. Cancer Prev.* 2015, 16, 5863–5868. [CrossRef] [PubMed]

23. Ibuki, Y.; Shikata, M.; Toyooka, T. γ-H2AX is a sensitive marker of DNA damage induced by metabolically activated 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Toxicol. Vitrol.* 2015, 29, 1831–1838. [CrossRef]

24. Dantoing, E.; Piton, N.; Salaün, M.; Thiberville, L.; Guiser, F. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. *Int. J. Mol. Sci.* 2021, 22, 6288. [CrossRef]

25. Wang, D.Y.; Salem, J.E.; Cohen, J.V.; Chandra, S.; Menz, C.; Ye, F.; Zhao, S.; Das, S.; Beckerman, K.E.; Ha, L., et al. Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol.* 2018, 4, 1721–1728. [CrossRef]

26. Travis, W.; Brambilla, E.; Burke, A.; Marx, A.; Nicholson, A. *WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, WHO Classification of Tumours*, 4th ed.; Travis, W., Brambilla, E., Burke, A., Marx, A., Nicholson, A., Eds.; World Health Organization: Lyon, France, 2015; Volume 7.

27. James, D.; Mary, K.; Christian, W. *TNM Classification of Malignant Tumours*, 8th ed.; James, D., Mary, K., Christian, W., Eds.; Wiley-Blackwell: Hoboken, NJ, USA, 2017.
28. Ministry of Health Labour and Welfare. Manual for Smoking Cessation and Management Fee for Nicotine Addiction. Available online: https://www.mhlw.go.jp/topics/tobacco/houkoku/061122f.html (accessed on 31 May 2022). (In Japanese).

29. Vennapusa, B.; Baker, B.; Kowanetz, M.; Boone, J.; Menzl, I.; Bruey, J.M.; Fine, G.; Mariathasan, S.; McCaffery, I.; Mocci, S.; et al. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. *Appl. Immunohistochem. Mol. Morphol.* 2019, 27, 92–100. [CrossRef]